Literature DB >> 2144198

Cushing's syndrome induced by medroxyprogesterone.

P K Merrin1, W D Alexander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2144198      PMCID： PMC1663616          DOI： 10.1136/bmj.301.6747.345-a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  The Cushing syndrome induced by medroxyprogesterone acetate.

Authors:  K Siminoski; P Goss; D J Drucker
Journal:  Ann Intern Med       Date:  1989-11-01       Impact factor: 25.391

2.  Oral high-dose medroxyprogesterone acetate causes adrenal suppression in patients with breast cancer.

Authors:  H Van Veelen; J Houwerzijl; T J Roding; T Tjabbes; R J Vermeer; D T Sleijfer; J J Pratt; P H Willemse
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

3.  Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; J J Pratt; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Oral medroxyprogesterone in the treatment of metastatic breast cancer.

Authors:  T Nemoto; J Patel; D Rosner; T L Dao
Journal:  J Surg Oncol       Date:  1986-08       Impact factor: 3.454
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.